<DOC>
	<DOC>NCT01608724</DOC>
	<brief_summary>The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>A multicenter, single arm, cohort study to evaluate the Efficacy and Safety of saxagliptin 5mg, once daily for 24 weeks, in patients with type 2 diabetes mellitus who are treatment naive or who have inadequate glycaemic control on metformin alone</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Diagnosed with type 2 diabetes Men or women who are &gt;18 years of age at time of consenting upon Visit 1 HbA1c &gt;7.5% and â‰¤11.0% Patients should be drug naive or treated with metformin alone on stable doses of for at least continues 8 weeks prior to Visit 1 Drug naive patients are defined as patients who have not received medical treatment for diabetes (insulin and/or oral hypo) Pregnant or breastfeeding patients Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes) Previous treatment with any DPPIV inhibitors or GLP1 analogue History of administration of any antihyperglycemic therapy (other than metformin) during the 8 weeks prior to Visit 1(12 weeks for previous TZD) Treatment with systemic glucocorticoids other than replacement therapy Inhaled, local injected and topical use of glucocorticoids is allowed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Type 2 DM</keyword>
</DOC>